Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R. 955 - Medicaid Reentry Act of 2021; H.R. 1319 - American Rescue Plan Act of 2021 (PL 117-2) Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022; Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2022; Interior, Environment, and Related Agencies Appropriations Act, 2022; Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022;
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ALKERMES, INC. via ALKERMES, INC.
2021 · second_quarter · Q2
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R. 955 - Medicaid Reentry Act of 2021; H.R. 1319 - American Rescue Plan Act of 2021 (PL 117-2) Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022; Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2022; Interior, Environment, and Related Agencies Appropriations Act, 2022; Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022;
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Source: Senate LDA
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R. 955 - Medicaid Reentry Act of 2021; H.R. 1319 - American Rescue Plan Act of 2021 (PL 117-2) Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022; Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2022; Interior, Environment, and Related Agencies Appropriations Act, 2022; Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022;
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R. 955 - Medicaid Reentry Act of 2021; H.R. 1319 - American Rescue Plan Act of 2021 (PL 117-2) Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022; Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2022; Interior, Environment, and Related Agencies Appropriations Act, 2022; Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022;
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R. 955 - Medicaid Reentry Act of 2021; H.R. 1319 - American Rescue Plan Act of 2021 (PL 117-2) Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022; Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2022; Interior, Environment, and Related Agencies Appropriations Act, 2022; Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022;
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) H.R. 133, Consolidated Appropriations Act, 2021 (PL 116-260)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) H.R. 133, Consolidated Appropriations Act, 2021 (PL 116-260)
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; H.R. 133 - Consolidated Appropriations Act, 2021 (PL 116-260) - Maintain Medicaid rebates for MAT products; SUPPORT Act (PL 115-271) - Maintain Medicaid rebates for MAT products;
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) H.R. 133, Consolidated Appropriations Act, 2021 (PL 116-260)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) H.R. 133, Consolidated Appropriations Act, 2021 (PL 116-260)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; H.R. 133 - Consolidated Appropriations Act, 2021 (PL 116-260) - Maintain Medicaid rebates for MAT products; SUPPORT Act (PL 115-271) - Maintain Medicaid rebates for MAT products;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; HR 8337 - Continuing Appropriations Act of 2021 - Maintain Medicaid rebates for MAT products; SUPPORT Act (PL 115-271) - Maintain Medicaid rebates for MAT products;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; Medicare Part D Restructuring;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; H.R. 133 - Consolidated Appropriations Act, 2021 (PL 116-260) - Maintain Medicaid rebates for MAT products; SUPPORT Act (PL 115-271) - Maintain Medicaid rebates for MAT products;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; HR 8337 - Continuing Appropriations Act of 2021 - Maintain Medicaid rebates for MAT products; SUPPORT Act (PL 115-271) - Maintain Medicaid rebates for MAT products;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; Medicare Part D Restructuring;
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) H.R. 133, Consolidated Appropriations Act, 2021 (PL 116-260)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)
Crisis Stabilization and Community Reentry Act of 2020
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Crisis Stabilization and Community Reentry Act of 2020
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Crisis Stabilization and Community Reentry Act of 2020
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) Advance the use of and funding for medications to treat serious mental illness Legislation to promote treatment amongst incarcerated individuals with serious mental illness S.2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019 S. 3312, HR 5909, Crisis Stabilization and Reentry Act;
Crisis Stabilization and Community Reentry Act of 2020
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Department of the Interior, Environment, and Related Agencies Appropriations Act, 2021
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Department of the Interior, Environment, and Related Agencies Appropriations Act, 2021
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Continuing Appropriations Act, 2021 and Other Extensions Act
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; HR 8337 - Continuing Appropriations Act of 2021 - Maintain Medicaid rebates for MAT products; SUPPORT Act (PL 115-271) - Maintain Medicaid rebates for MAT products;
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) H.R. 133, Consolidated Appropriations Act, 2021 (PL 116-260)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; HR 8337 - Continuing Appropriations Act of 2021 - Maintain Medicaid rebates for MAT products; SUPPORT Act (PL 115-271) - Maintain Medicaid rebates for MAT products;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; H.R. 133 - Consolidated Appropriations Act, 2021 (PL 116-260) - Maintain Medicaid rebates for MAT products; SUPPORT Act (PL 115-271) - Maintain Medicaid rebates for MAT products;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; Medicare Part D Restructuring;
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) Advance the use of and funding for medications to treat serious mental illness Legislation to promote treatment amongst incarcerated individuals with serious mental illness S.2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019 S. 3312, HR 5909, Crisis Stabilization and Reentry Act;
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Crisis Stabilization and Community Reentry Act of 2020
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) Advance the use of and funding for medications to treat serious mental illness Legislation to promote treatment amongst incarcerated individuals with serious mental illness S.2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019 S. 3312, HR 5909, Crisis Stabilization and Reentry Act;
Crisis Stabilization and Community Reentry Act of 2020
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Crisis Stabilization and Community Reentry Act of 2020
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Crisis Stabilization and Community Reentry Act of 2020
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Further Additional Continuing Appropriations Act, 2019
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act HR 6 (PL 115-271) The Support Act funding, including Comprehensive Opioid Recovery Centers
Further Additional Continuing Appropriations Act, 2019
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5)
Further Additional Continuing Appropriations Act, 2019
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act HR 6 (PL 115-271) The Support Act funding, including Comprehensive Opioid Recovery Centers
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; Medicare Part D Restructuring;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act Medicare Part D Restructuring
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; Medicare Part D Restructuring;
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act HR 6 (PL 115-271) The Support Act funding, including Comprehensive Opioid Recovery Centers
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act HR 6 (PL 115-271) The Support Act funding, including Comprehensive Opioid Recovery Centers
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act HR 6 (PL 115-271) The Support Act funding, including Comprehensive Opioid Recovery Centers
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; Medicare Part D Restructuring;
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act Medicare Part D Restructuring
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) Advance the use of and funding for medications to treat serious mental illness Legislation to promote treatment amongst incarcerated individuals with serious mental illness S.2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 6 - SUPPORT for Patient and Communities Act (PL 115-271) PL# 114-198 - 21st Century Cures Opioid implementation Advance the use of and funding for medications to treat serious mental illness Legislation to promote treatment amongst incarcerated individuals with serious mental illness
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 6 - SUPPORT for Patient and Communities Act (PL 115-271) PL# 114-198 - 21st Century Cures Opioid implementation Advance the use of and funding for medications to treat serious mental illness
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 6 - SUPPORT for Patient and Communities Act (PL 115-271) PL# 114-198 - 21st Century Cures Opioid implementation Advance the use of and funding for medications to treat serious mental illness
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2456/HR 5311 - Comprehensive Addiction and Recovery 2.0 Act of 2018
Comprehensive Opioid Recovery Centers Act of 2018
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act
Comprehensive Opioid Recovery Centers Act of 2018
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018 PL# 114-198 - 21st Century Cures Opioid implementation
Comprehensive Opioid Recovery Centers Act of 2018
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2456/HR 5311 - Comprehensive Addiction and Recovery 2.0 Act of 2018
Comprehensive Opioid Recovery Centers Act of 2018
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act H.R.5786 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019 S.3024 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019 H.R.5952 Commerce, Justice, Science and Related Agencies Appropriations Act, 2019 S.3072 115th Congress (2017-2018) Commerce, Justice, Science and Related Agencies Appropriations Act, 2019 S.3156 (2017-2018) Department of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2019 House Discussion Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Energy and Water, Legislative Branch, and Military Construction and Veterans Affairs Appropriations Act, 2019
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act H.R. 6157 - Appropriations for DOD, Labor/HHS/Education and Continuing Appropriations for all other agencies H.R. 5895 - The Energy and Water Development and Related Agencies Appropriations Act
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act H.R.5786 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019 S.3024 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019 H.R.5952 Commerce, Justice, Science and Related Agencies Appropriations Act, 2019 S.3072 115th Congress (2017-2018) Commerce, Justice, Science and Related Agencies Appropriations Act, 2019 S.3156 (2017-2018) Department of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2019 House Discussion Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018 PL# 114-198 - 21st Century Cures Opioid implementation
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act H.R. 6157 - Appropriations for DOD, Labor/HHS/Education and Continuing Appropriations for all other agencies H.R. 5895 - The Energy and Water Development and Related Agencies Appropriations Act
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 695 - Department of Defense Appropriations Act 5.756 - First Step Act
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2456/HR 5311 - Comprehensive Addiction and Recovery 2.0 Act of 2018
Comprehensive Opioid Recovery Centers Act of 2018
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act
Comprehensive Opioid Recovery Centers Act of 2018
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018
Comprehensive Opioid Recovery Centers Act of 2018
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018 PL# 114-198 - 21st Century Cures Opioid implementation
Comprehensive Opioid Recovery Centers Act of 2018
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2456/HR 5311 - Comprehensive Addiction and Recovery 2.0 Act of 2018
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018 PL# 114-198 - 21st Century Cures Opioid implementation
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018
ALKERMES, INC. via ALKERMES, INC.
2021 · first_quarter · Q1
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R. 955 - Medicaid Reentry Act of 2021; H.R. 1319 - American Rescue Plan Act of 2021 (PL 117-2) Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022; Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2022; Interior, Environment, and Related Agencies Appropriations Act, 2022; Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022;
Filing targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2020 · fourth_quarter · Q4
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) H.R. 133, Consolidated Appropriations Act, 2021 (PL 116-260)
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; H.R. 133 - Consolidated Appropriations Act, 2021 (PL 116-260) - Maintain Medicaid rebates for MAT products; SUPPORT Act (PL 115-271) - Maintain Medicaid rebates for MAT products;
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Filing targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2020 · third_quarter · Q3
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; HR 8337 - Continuing Appropriations Act of 2021 - Maintain Medicaid rebates for MAT products; SUPPORT Act (PL 115-271) - Maintain Medicaid rebates for MAT products;
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2020 · second_quarter · Q2
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 1329 - Medicaid Reentry Act S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94) HR 7609 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021 HR 7614 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2021 HR 7612 - Interior, Environment, and Related Agencies Appropriations Act, 2021 Department of Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) S. 3312/HR 5909 - Crisis Stabilization and Community Reentry Act S. 2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues - HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019;
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2020 · first_quarter · Q1
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; Medicare Part D Restructuring;
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) Advance the use of and funding for medications to treat serious mental illness Legislation to promote treatment amongst incarcerated individuals with serious mental illness S.2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019 S. 3312, HR 5909, Crisis Stabilization and Reentry Act;
ALKERMES, INC. via ALKERMES, INC.
2019 · fourth_quarter · Q4
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; Medicare Part D Restructuring;
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) Advance the use of and funding for medications to treat serious mental illness Legislation to promote treatment amongst incarcerated individuals with serious mental illness S.2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019
ALKERMES, INC. via ALKERMES, INC.
2019 · third_quarter · Q3
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act Medicare Part D Restructuring
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act HR 6 (PL 115-271) The Support Act funding, including Comprehensive Opioid Recovery Centers
ALKERMES, INC. via ALKERMES, INC.
2019 · second_quarter · Q2
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 6 - SUPPORT for Patient and Communities Act (PL 115-271) PL# 114-198 - 21st Century Cures Opioid implementation Advance the use of and funding for medications to treat serious mental illness
ALKERMES, INC. via ALKERMES, INC.
2019 · first_quarter · Q1
Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 6 - SUPPORT for Patient and Communities Act (PL 115-271) PL# 114-198 - 21st Century Cures Opioid implementation Advance the use of and funding for medications to treat serious mental illness
ALKERMES, INC. via ALKERMES, INC.
2018 · fourth_quarter · Q4
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 695 - Department of Defense Appropriations Act 5.756 - First Step Act
Maintain six protected classes for depression and schizophrenia under Medicare Part D Drug pricing issues
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018 PL# 114-198 - 21st Century Cures Opioid implementation
ALKERMES, INC. via ALKERMES, INC.
2018 · third_quarter · Q3
Public law #114-198, 21st Century Cures Opioid Implementation Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act H.R. 6157 - Appropriations for DOD, Labor/HHS/Education and Continuing Appropriations for all other agencies H.R. 5895 - The Energy and Water Development and Related Agencies Appropriations Act
ALKERMES, INC. via ALKERMES, INC.
2018 · second_quarter · Q2
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act H.R.5786 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019 S.3024 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019 H.R.5952 Commerce, Justice, Science and Related Agencies Appropriations Act, 2019 S.3072 115th Congress (2017-2018) Commerce, Justice, Science and Related Agencies Appropriations Act, 2019 S.3156 (2017-2018) Department of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2019 House Discussion Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
ALKERMES, INC. via ALKERMES, INC.
2018 · first_quarter · Q1
Public law #114-198, 21st Century Cures Opioid Implementation Awareness of outcomes data and the need for training on all medication assisted treatment
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act PL 115-141 Consolidated Appropriations Act of 2018 Ensure availability of all treatments for addiction through the Substance Abuse & Mental Health Services Administration. Advance use of addiction medicines in the Bureau of Prisons and within criminal justice funding (Byrne Jag)
ALKERMES, INC. via ALKERMES, INC.
2017 · fourth_quarter · Q4
Maintain six protected classes for depression and schizophrenia under Medicare Part D
Advance the use, and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act PL 115-90 Continuing Appropriations for FY18 PL 115-96 To amend the HomeLand Security Act of 2002 Ensure availability of all treatments for addiction in the Veterans Affairs and Indian Health Services, and through the Substance Abuse & Mental Health Services Administration. Advance use of addiction medicines in the Bureau of Prisons and within criminal justice funding (Byrne Jag)
ALKERMES, INC. via ALKERMES, INC.
2017 · third_quarter · Q3
Confronting the opioid and mental illness epidemic HR 1682 America Health Care Act of 2017, Coverage for the treatment of opioid dependence & serious mental illness H.R 1628, Better Care Reconciliation Act of 2017, Coverage for the treatment of opioid dependence & serious mental illness
Public law #114-198, Cures Opioid Funding Implementation H.R. 2430 FDA Reauthorization Act of 2017 S.934 FDA Reauthorization Act of 2017
Maintain Medicare's six protected classes for depression and schizophrenia
ALKERMES, INC. via ALKERMES, INC.
2017 · second_quarter · Q2
Public law #114-198, Cures Opioid Funding Implementation H.R. 2430 FDA Reauthorization Act of 2017 S.934 FDA Reauthorization Act of 2017
Advance the use, and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act PL#115-31 Consolidated Appropriations Act of 2017 FY18 Appropriations Act H.R.2998 Military Construction, Veterans Affairs, & Related Agencies Appropriations Act of 2018 Ensure availability of all treatments for addiction in the Veterans Affairs and Indian Health Services, and through the Substance Abuse & Mental Health Services Administration. Advance use of addiction medicines in the Bureau of Prisons and within criminal justice funding (Byrne Jag)
ALKERMES, INC. via ALKERMES, INC.
2017 · first_quarter · Q1
Confronting the opioid and mental illness epidemic HR 1682 America Health Care Act of 2017, Coverage for the treatment of opioid dependence & serious mental illness
Maintain Medicare's six protected class for depression and schizophrenia S. 648, Medicare Formulary Improvement Act of 2015
Advance the use, and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings Funding of Comprehensive Addiction and Recovery Act FY17 Appropriations FY18 Appropriations Ensure availability of all treatments for addiction in the Veterans Affairs and Indian Health Services, and through the Substance Abuse & Mental Health Services Administration. Advance use of addiction medicines in the Bureau of Prisons and within criminal justice funding (Byrne Jag)
ALKERMES, INC. via ALKERMES, INC.
2016 · fourth_quarter · Q4
Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 6 the 21st Century Cures Act, Funding for Opioid Treatment.
Maintain Medicare's six protected class status for depression and schizophrenia S. 648, Medicare Formulary Improvement Act of 2015
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings S. 524/HR 953 Comprehensive Addiction and Recovery Act S. 1696/HR 3420 Departments of Labor, Health and Human Services, and Education and Related Agencies Act, 2016 (implementation of opioid treatment funding) Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2017. Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2017. Making appropriations for Labor, Health and Human Services, and Education and Related Agencies Act for the fiscal year ending September 30, 2017. Making appropriations for Commerce, Justice and Science for the fiscal year ending September 30, 2017.
ALKERMES, INC. via ALKERMES, INC.
2016 · third_quarter · Q3
Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 6 the 21st Century Cures Act
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings S. 524/HR 953 Comprehensive Addiction and Recovery Act S. 1696/HR 3420 Departments of Labor, Health and Human Services, and Education and Related Agencies Act, 2016 (implementation of opioid treatment funding) Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2017. Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2017. Making appropriations for Labor, Health and Human Services, and Education and Related Agencies Act for the fiscal year ending September 30, 2017. Making appropriations for Commerce, Justice and Science for the fiscal year ending September 30, 2017.
ALKERMES, INC. via ALKERMES, INC.
2016 · second_quarter · Q2
Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 6 the 21st Century Cures Act
Maintain Medicare's six protected class status for depression and schizophrenia S. 648, Medicare Formulary Improvement Act of 2015
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings S. 524/HR 953 Comprehensive Addiction and Recovery Act S. 1696/HR 3420 Departments of Labor, Health and Human Services, and Education and Related Agencies Act, 2016 (implementation of opioid treatment funding) Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2017. Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2017. Making appropriations for Labor, Health and Human Services, and Education and Related Agencies Act for the fiscal year ending September 30, 2017.
ALKERMES, INC. via ALKERMES, INC.
2016 · first_quarter · Q1
Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 6 the 21st Century Cures Act
Confronting the opioid and mental illness epidemic HR 2872, Opioid Addiction and Modernization Act
Maintain Medicare's six protected class status for depression and schizophrenia S. 648, Medicare Formulary Improvement Act of 2015
ALKERMES, INC. via ALKERMES, INC.
2015 · fourth_quarter · Q4
Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 639/S 481, Improving Regulatory Transparency Act for New Medical Therapies Act
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings S. 524/HR 954 Comprehensive Addiction and Recovery Act S. 1695/HR 3420 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016 (opioid funding) S.1695/HR 2578 Commerce, Justice, Science and Related Agencies Appropriations Act of 2016 (Bureau of Prisons medication pilot, inclusion of medications in Byrne Jag) HR 2029 The Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2016 (Opioid Medication Funding, Bureau of Prisons medication pilot, inclusion of medications in Byrne Jag)
ALKERMES, INC. via ALKERMES, INC.
2015 · third_quarter · Q3
Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 639/S 481, Improving Regulatory Transparency Act for New Medical Therapies Act
Maintain the program's six protected classes with respect to depression and schizophrenia S. 648, Medicare Formulary Improvement Act of 2015
Confronting the opioid and mental illness epidemic HR 2872, Opioid Addiction and Modernization Act
ALKERMES, INC. via ALKERMES, INC.
2015 · second_quarter · Q2
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings S. 524/HR 954 Comprehensive Addiction and Recovery Act S. 1695/HR 3420 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016 Senate bill/HR 2578, Commerce, Justice, Science and Related Agencies Appropriations Act of 2016 (Bureau of Prisons medication pilot, inclusion of medications in Byrne Jag)
Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 639/S 481, Improving Regulatory Transparency Act for New Medical Therapies Act
ALKERMES, INC. via ALKERMES, INC.
2015 · first_quarter · Q1
Discuss need for educational resources and the use of Vivitrol for public health
Advance the use of FDA-approved medicines to treat addiction in criminal justice settings H.R.3465/S.1690, The Second Chance Act of 2013 - use of FDA approved medicines in criminal justice settings S.1675, Recidivism Reduction and Public Safety Act of 2013 - us of FDA approved medicines in criminal justice settings
Maintain the program's six protected classes with respect to depression and schizophrenia
ALKERMES, INC. via ALKERMES, INC.
2014 · fourth_quarter · Q4
Advance the use of FDA-approved medicines to treat addiction in criminal justice settings H.R.3465/S.1690, The Second Chance Act of 2013 - use of FDA approved medicines in criminal justice settings S.1675, Recidivism Reduction and Public Safety Act of 2013 - use of FDA approved medicines in criminal justice settings
Maintain the program's six protected classes with respect to depression and schizophrenia
DEA regulatory transparency in controlled substances scheduling person DEA regulatory transparency in issuing research licenses and quotas
ALKERMES, INC. via ALKERMES, INC.
2014 · third_quarter · Q3
Discuss need for educational resources and the use of Vivitrol for public health
Maintain the program's six protected classes with respect to depression and schizophrenia
Advance the use of FDA-approved medicines to treat addiction in criminal justice settings H.R.3465/S.1690, The Second Chance Act of 2013 - use of FDA-approved medicines in criminal justice settings S.1675, Recidivism Reduction and Public Safety Act of 2013 - use of FDA-approved medicines in criminal justice settings Comprehensive Addiction Recovery Act of 2014
ALKERMES, INC. via ALKERMES, INC.
2014 · second_quarter · Q2
Advance the use of FDA-approved medicines to treat addiction in criminal justice settings H.R.3465/S.1690, The Second Chance Act of 2013 - use of FDA-approved medicines in criminal justice settings S.1675, Recidivism Reduction and Public Safety Act of 2013 - use of FDA-approved medicines in criminal justice settings
Maintain the program's six protected classes with respect to depression and schizophrenia
DEA regulatory transparency in controlled substances scheduling person DEA regulatory transparency in issuing research licenses and quotas
ALKERMES, INC. via ALKERMES, INC.
2014 · first_quarter · Q1
Maintain Medicare's Six Protected Classes status for depression and schizophrenia
Advance the use of FDA-approved medicines to treat addiction in criminal justice settings H.R.3465/S.1690, The Second Chance Act of 2013 - the use of FDA-approved medicines in criminal justice settings S.1675, Recidivism Reduction and Public Safety Act of 2013 - the use of FDA-approved medicines in criminal justice settings
Ensure access to medications in various crimial justice settings
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
ALKERMES, INC. via ALKERMES, INC.
2013 · fourth_quarter · Q4
Advance the use of FDA-approved medicines to treat addiction in criminal justice settings H.R.3465/S.1690, The Second Chance Act of 2013 - use of FDA-approved medicines in criminal justice settings S.1675, Recidivism Reduction and Public Safety Act of 2013 - use of FDA-approved medicines in criminal justice settings
DEA regulatory transparency in controlled substances scheduling process DEA regulatory transparency in issuing research licenses and quotas
Maintain the program's six protected classes with respect to depression and schizophrenia
ALKERMES, INC. via ALKERMES, INC.
2013 · third_quarter · Q3
Discuss need for educational resources and status of Vivitrol in public health.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA)
ALKERMES, INC. via ALKERMES, INC.
2013 · second_quarter · Q2
Discuss need for educational resources and status of Vivitrol in public health.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA)
ALKERMES, INC. via ALKERMES, INC.
2013 · first_quarter · 1A
Discuss need for educational resources and status of Vivitrol in public health.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA)
ALKERMES, INC. via ALKERMES, INC.
2013 · first_quarter · Q1
Discuss need for educational resources and status of Vivitrol in public health.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA)
ALKERMES, INC. via ALKERMES, INC.
2012 · fourth_quarter · Q4
Discuss need for educational resources and status of Vivitrol in public health
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA)
ALKERMES, INC. via ALKERMES, INC.
2012 · third_quarter · Q3
Discuss need for educational resources and status of Vivitrol in public health
Filing targets: HOUSE OF REPRESENTATIVES, Substance Abuse & Mental Health Services Administration (SAMHSA)
ALKERMES, INC. via ALKERMES, INC.
2012 · second_quarter · Q2
Introduction to Vivitrol. Discuss need for educational resources and public health matters.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
ALKERMES, INC. via ALKERMES, INC.
2012 · first_quarter · 1A
Provider education programs and other educational resources related to Vivitrol.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
ALKERMES, INC. via ALKERMES, INC.
2012 · second_quarter · RA
Improvement to and appropriations for substance abuse treatment; substance abuse treatment and VIVITROL educational resources.
ALKERMES, INC. via ALKERMES, INC.
2011 · fourth_quarter · Q4
Discussion of educational resources for health professionals
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2011 · third_quarter · Q3
Discussion of educational resources for health professionals
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH)
ALKERMES, INC. via ALKERMES, INC.
2011 · fourth_quarter · RA
Improvements to and appropriations for substance abuse treatment; substance abuse treatment and VIVITROL educational resources;
ALKERMES, INC. via ALKERMES, INC.
2011 · second_quarter · Q2
To provide information about alcohol and opioid dependence and medication assisted treatment.
Filing targets: HOUSE OF REPRESENTATIVES, Substance Abuse & Mental Health Services Administration (SAMHSA)
ALKERMES, INC. via ALKERMES, INC.
2011 · first_quarter · Q1
Provider education programs and other educational resources related to VIVITROL
Filing targets: Substance Abuse & Mental Health Services Administration (SAMHSA)
ALKERMES, INC. via ALKERMES, INC.
2011 · first_quarter · RA
The treatment of substance abuse, including the appropriation of funding specifically for medication assisted treatment.
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 6 - SUPPORT for Patient and Communities Act (PL 115-271) PL# 114-198 - 21st Century Cures Opioid implementation Advance the use of and funding for medications to treat serious mental illness Legislation to promote treatment amongst incarcerated individuals with serious mental illness
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5) S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings H.J. Res 31, Consolidated Appropriations Act of 2019 (PL 116-6) H.J. Res 28, FY19 Further Additional Continuing Appropriation Act (PL 116-5)
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Public law #114-198, 21st Century Cures Opioid Implementation Awareness of outcomes data and the need for training on all medication assisted treatment
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2456/HR 5311 - Comprehensive Addiction and Recovery 2.0 Act of 2018
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Confronting the opioid and mental illness epidemic Awareness of the need for treatment system reform and access to all FDA-approved medications
Public law #114-198, 21st Century Cures Opioid Implementation Awareness of outcomes data and the need for training on all medication assisted treatment
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Advance the use, and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act PL#115-31 Consolidated Appropriations Act of 2017 FY18 Appropriations Act H.R.2998 Military Construction, Veterans Affairs, & Related Agencies Appropriations Act of 2018 Ensure availability of all treatments for addiction in the Veterans Affairs and Indian Health Services, and through the Substance Abuse & Mental Health Services Administration. Advance use of addiction medicines in the Bureau of Prisons and within criminal justice funding (Byrne Jag)
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Maintain Medicare's six protected classes for depression and schizophrenia
Confronting the opioid and mental illness epidemic HR 1682 America Health Care Act of 2017, Coverage for the treatment of opioid dependence & serious mental illness H.R 1628, Better Care Reconciliation Act of 2017, Coverage for the treatment of opioid dependence & serious mental illness
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Public law #114-198, Cures Opioid Funding Implementation Reauthorization of the Prescription Drug User Fee Act (PDUFA)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Confronting the opioid and mental illness epidemic HR 2872, Opioid Addiction and Modernization Act HR 4981, Opioid Use Disorder Treatment Expansion and Modernization Act S. 524, Comprehensive Addiction and Recovery Act Implementation Further Continuing and Security Assistance Appropriations Act, 2017 - $500M in opioid treatment funding
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Confronting the opioid and mental illness epidemic HR 2872, Opioid Addiction and Modernization Act HR 4981, Opioid Use Disorder Treatment Expansion and Modernization Act
Maintain Medicare's six protected class status for depression and schizophrenia S. 648, Medicare Formulary Improvement Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Confronting the opioid and mental illness epidemic HR 2872, Opioid Addiction and Modernization Act HR 4981, Opioid Use Disorder Treatment Expansion and Modernization Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings S. 524/HR 953 Comprehensive Addiction and Recovery Act S. 1696/HR 3420 Departments of Labor, Health and Human Services, and Education and Related Agencies Act, 2016 (implementation of opioid treatment funding) Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2017. Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2017.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Maintain the program's six protected classes with respect to depression and schizophrenia S. 648, Medicare Formulary Improvement Act of 2015
Confronting the opioid and mental illness epidemic HR 2872, Opioid Addiction and Modernization Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings S. 524/HR 954 Comprehensive Addiction and Recovery Act S. 1695/HR 3420 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016 Senate bill/HR 2578, Commerce, Justice, Science and Related Agencies Appropriations Act of 2016 (Bureau of Prisons medication pilot, inclusion of medications in Byrne Jag)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Maintain the program's six protected classes with respect to depression and schizophrenia S. 648, Medicare Formulary Improvement Act of 2015
Confronting the opioid and mental illness epidemic HR 2872, Opioid Addiction and Modernization Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
DEA regulatory transparency in controlled substances scheduling person DEA regulatory transparency in issuing research licenses and quotas
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Discuss need for educational resources and the use of Vivitrol for public health
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
DEA regulatory transparency in controlled substances scheduling person DEA regulatory transparency in issuing research licenses and quotas H.R.4299,Improving regulatory transparency for new medical therapies act S.2866,Regulatory transparency, patient access, and effective drug enforcement act
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Discuss need for educational resources and the use of Vivitrol for public health
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE
Discuss need for educational resources and the use of Vivitrol for public health
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institute on Alcohol Abuse & Alcoholism (NIAA), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)